Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 379

The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Open access
Snowden, John A., Sánchez-Ortega, Isabel, Corbacioglu, Selim, Basak, Grzegorz W., Chabannon, Christian, de la Camara, Rafael, Dolstra, Harry, Duarte, Rafael F., Glass, Bertram, Greco, Raffaella, Lankester, Arjan C., Mohty, Mohamad, Neven, Bénédicte, de Latour, Régis Peffault, Pedrazzoli, Paolo, Peric, Zinaida, Yakoub-Agha, Ibrahim, Sureda, Anna, Kröger, Nicolaus, for the European Society for Blood and Marrow Transplantation (EBMT)·2022·Bone Marrow Transplantation

Abstract

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41409-022-01691-w

Cites

230 of 230 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 230 references

Cited by

See all 379

Metadata

Authors
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., Lankester, A. C., Mohty, M., Neven, B., de Latour, R. P., Pedrazzoli, P., Peric, Z., Yakoub-Agha, I., Sureda, A., Kröger, N., & for the European Society for Blood and Marrow Transplantation (EBMT)
Venue
Bone Marrow Transplantation
Published
2022-05-19
Volume
57
Issue
8
Pages
1217-1239
ISSN
  • 0268-3369 (ISSN-L)
  • 1476-5365
OpenAlex
W4280552588
Cited by
379
References
230
FWCI
49.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. https://app.cochat.ai/papers/10.1038/s41409-022-01691-w
The paper
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., Lankester, A. C., Mohty, M., Neven, B., de Latour, R. P., Pedrazzoli, P., Peric, Z., Yakoub-Agha, I., Sureda, A., Kröger, N., & for the European Society for Blood and Marrow Transplantation (EBMT). (2022). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-022-01691-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.